Skip to content

A randomized controlled trial for comparing safety and effectiveness of three endoscopic minimally invasive surgeries in the treatment of SiewertII adenocarcinoma of the esophagogastric junction

A randomized controlled trial for comparing safety and effectiveness of three endoscopic minimally invasive surgeries in the treatment of SiewertII adenocarcinoma of the esophagogastric junction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042802
Enrollment
Unknown
Registered
2021-01-28
Start date
2021-01-31
Completion date
Unknown
Last updated
2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

A Group:total laparoscopic transthoracic approach overlap reconstruction
B Group:total thora-laparoscopic combined Sweet esophagectomy
C Group:total thora-laparoscopic combined Ivor - Lewis esophagectomy

Sponsors

Affiliated Xijing Hospital of Airforce Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed as Siewert type II adenocarcinoma of esophagogastric junction by endoscopy or histology; 2. The tumor met the resectable condition: ct1-t3, no distant metastasis (N0-N1 and M0); 3. Patients who underwent total laparoscopic thoracic approach overlap reconstruction or total thoracoscopic combined with sweet or total thoracoscopic combined with Ivor Lewis; 4. Patients who have not received chemotherapy or radiotherapy in the past; 5. Patients with ECoG <= 2; 6. (American Society of anesthesiologists) patients with ASA < 3; 7. Subjects with nrs2002 nutritional score <= 2; 8. Subjects who signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients over 75 years old; 2. Those patients with enlarged lymph nodes in the upper mediastinum over 5 mm; 3. Patients with other malignant tumor diseases; 4. Patients with a history of gastroesophageal surgery; 5. Patients who have received neoadjuvant chemotherapy or radiotherapy in the past; 6. Patients with other serious organ dysfunction; 7. Patients with Karnofsky index lower than 80.

Design outcomes

Secondary

MeasureTime frame
time of operation;postoperative hospitalization duration;Incidence of postoperative reflux within 1 year;The recurrence and metastasis rate 1 year after operation;One-year survival rate after surgery;Incidence of cardiopulmonary complications;Incidence of postoperative bleeding;

Primary

MeasureTime frame
the positive rate of resection margin residual cancer;Average number of dissected lymph nodes;Time of first exhaust and defecation after operation;anastomotic leakage;postoperative infection;

Countries

China

Contacts

Public ContactGang Ji

Affiliated Xijing Hospital of Airforce Military Medical University

yang_jun1018@163.com+86 13572152581

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026